[Highlight] Why Dog Longevity Drugs Are the Fastest Path to Human Longevity with Celine Halioua

Hey. Ben Kesnoka here, cofounder and general partner of Village Global, a network native venture firm. What you're about to hear is a clip from a longer conversation. If you'd like to listen to the full length version, find the link in the description. And, of course, subscribe so you don't miss the next one. Enjoy. When you think about the company ten years out, what do you imagine loyal looking like? I think we'll be a multi subsidiary company that's developing numerous products for dog longevity, probably for cat longevity by that time, and also human drugs. I think we'll also be working on early discovery and r and d. So right now, I'd consider us more of like a clinical company. We take an existing biological hypotheses and ideas, and we turn those into drug products and then prove, hopefully, that they are efficacious and safe for lifespan extension. But we're not, like, de novo discovering biology of aging. Right? In ten years, I think we're gonna have an extremely robust pipeline and discovery unit that's ideating new mechanisms and new ways to intervene in the aging process to hopefully slow it, but potentially even reverse it one day too, which is the holy grail. Right? And I also think in ten years, aging will be a lot more consensus, and most pharma companies will have an explicit aging division within their organizations. Why do you think pharma companies have been so slow to adopt this? Because it's not canonically considered something you develop a drug for. Like, one of the biggest risks, when you guys invested, besides random chick, never done anything, besides, like, being associate at a two person venture fund, didn't finish her PhD, and, like, very disagreeable, which, you know, adds a lot of other risks, besides all of that risk that you guys took. And, oh, by the way, it's just an idea and literally nothing else, and a, like, mediocrely designed slide deck. Sounds like a great founder to me. Could've gone worse. It it also was you know, I had this idea that the FDA would accept the drug could be approved for lifespan extension and health span extension itself even though it had never been done before and was canonically considered impossible. And, I mean, that that was the case. Right? This was not considered like, a pharmaceutical is developed for a disease like Alzheimer's, like cancer, like the flu. It is not developed for, hey. You're aging. Oh, you're still aging. Oh, you're aging at a little bit of a faster rate now. You're aging better. You're aging worse. Right? That that isn't something that you develop a pharmaceutical for. And so I didn't think that had to be the case. I didn't think that was true. I didn't think it was inherent. I thought it was a self limitation of the field, but nobody had shown before that that was possible. So I think there was just any …